AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37022717
Drug: Cyclosporine solution,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine solution, 0.1%
Trial: 37022774
Drug: Atellica® IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atellica® IM High-Sensitivity Troponin I (hs-cTnI) assay with a threshold of <10 ng/L
Trial: 37023284
Drug: Higher proportions
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher proportions of network members engaging in heavy alcohol use, regular cannabis use, or other drug use
Trial: 37023374
Drug: Peritumoral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritumoral injection of 0.5% lidocaine, 7-10 minutes before surgery
Trial: 37023398
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and Alternative Medicine
Trial: 37023451
Drug: Levonorgestrel 52-mg
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel 52-mg Intrauterine Device
Trial: 37023455
Drug: Levonorgestrel 52-mg
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel 52-mg intrauterine device (IUD)
Trial: 37023659
Drug: Monthly cash
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly cash payment of 300 Rand conditional on school enrollment of index young women
Trial: 37023705
Drug: Ipatasertib 300
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib 300 mg daily, carboplatin AUC2, paclitaxel 80 mg m-2 days 1, 8, and 15 every 28 days (Arm A)
Trial: 37023705
Drug: Ipatasertib 400
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib 400 mg daily, carboplatin AUC2 days 1, 8, and 15 every 28 days (Arm B)
Trial: 37023705
Drug: Ipatasertib 300
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib 300 mg 21 days on 7 days off, capecitabine 750 mg m-2, twice a day, 7 days on 7 days off, atezolizumab 840 mg days 1 and 15 every 28 days (Arm C)
Trial: 37023789
Drug: Mandatory split-dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandatory split-dose bowel preparation (SDBP)
Trial: 37023789
Drug: Optional split-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optional split-dose bowel preparation (SDBP)
Trial: 37023987
Drug: Stereotactic Ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic Ablative Radiotherapy in combination with Durvalumab
Trial: 37024249
Drug: RMC-035 (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMC-035 (1.3 or 0.65 mg/kg intravenous infusion, five doses based on presurgery estimated glomerular filtration rate)
Trial: 37024420
Drug: D-VMP (Daratumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-VMP (Daratumumab + Bortezomib 1.3 mg/m² + Melphalan + Prednisone)
Trial: 37024420
Drug: VMP (Bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMP (Bortezomib 1.3 mg/m² + Melphalan + Prednisone)
Trial: 37024478
Drug: Intravitreal anti-VEGF
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal anti-VEGF injections (IVI) during COVID-19 lockdown
Trial: 37024478
Drug: Delayed or
RxNorm normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed or missed intravitreal anti-VEGF injections (IVI) during COVID-19 lockdown
Trial: 37024520
Drug: WVT078 (anti-BCMA×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WVT078 (anti-BCMA× anti-CD3 bispecific antibody) administered intravenously once weekly at doses of 48-250 µg/kg (n=26)
Trial: 37024520
Drug: WVT078 (anti-BCMA×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WVT078 (anti-BCMA× anti-CD3 bispecific antibody)
Trial: 37024811
Drug: Potential proof-of-concept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential proof-of-concept for adoptive T cell therapy against CMV and VZV
Trial: 37024868
Drug: Cohort B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort B (5 NF135-infected mosquito bites and presumptive treatment with artemether/lumefantrine)
Trial: 37024966
Drug: Goal-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed fluid therapy using balanced crystalloids
Trial: 37025256
Drug: Esketamine plus
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine plus oral antidepressant (AD)
Trial: 37025758
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg or 480 mg IV) administered for up to 2 years until progression, combined with SRS (15-21 Gy) delivered within 14 days after the first dose of nivolumab.
Trial: 37025758
Drug: SRS (15-21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRS (15-21 Gy) to all un-irradiated BM delivered within 14 days after the first dose of nivolumab.
Trial: 37025758
Drug: Nivolumab and
RxNorm normalized name: nivolumab and relatlimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab and SRS combination treatment.
Trial: 37026453
Drug: Prescribed aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed aerobic and resistance exercise during neoadjuvant therapy (Arm B)
Trial: 37026551
Drug: Sacubitril/valsartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan 200 mg/d
Trial: 37026551
Drug: Sacubitril/valsartan 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan 400 mg/d
Trial: 37026799
Drug: I arm
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I arm (ibrutinib 420 mg/day for 6 months after 9 months of obinutuzumab-ibrutinib induction)
Trial: 37026799
Drug: I-FCG arm
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-FCG arm (up to 4 cycles of fludarabine/cyclophosphamide-obinutuzumab 1000 mg alongside ibrutinib)
Trial: 37026822
Drug: Kinesio taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio taping along with physical therapy intervention
Trial: 37026822
Drug: Night splinting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night splinting along with physical therapy intervention
Trial: 37026822
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy intervention alone (Control)
Trial: 37027186
Drug: High-Intensity Interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Interval Training (HIIT) - 16-week, thrice-weekly intervention, including a 5-minute warm-up at 10% POmax, 10 sets of alternating 1-minute high-intensity (90% POmax) and 1-minute recovery (10% POmax) intervals, and a 5-minute cooldown (10% POmax)
Trial: 37027198
Drug: Blended care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended care intervention for BZRA discontinuation
Trial: 37027812
Drug: Investigational immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational immunotherapy agents
Trial: 37028103
Drug: Non-tobacco flavored
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-tobacco flavored e-cigarette solutions
Trial: 37028103
Drug: Tobacco flavored
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco flavored e-cigarette solutions
Trial: 37028103
Drug: Strawberry flavored
RxNorm normalized name: SODIUM FLUORIDE 0.122 g in 100 mL DENTAL PASTE [Botao Kids Strawberry Flavored with Fluoride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry flavored e-cigarette solution
Trial: 37028433
Drug: Sovleplenib 100
RxNorm normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovleplenib 100 mg
Trial: 37028433
Drug: Sovleplenib 200
RxNorm normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovleplenib 200 mg
Trial: 37028433
Drug: Sovleplenib 300
RxNorm normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovleplenib 300 mg
Trial: 37028433
Drug: Sovleplenib 400
RxNorm normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovleplenib 400 mg
Trial: 37028433
Drug: Sovleplenib 300
RxNorm normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovleplenib 300 mg (overall response rate)
Trial: 37028433
Drug: Sovleplenib 300
RxNorm normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovleplenib 300 mg (durable response rate)
Trial: 37028433
Drug: Sovleplenib (treatment-emergent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovleplenib (treatment-emergent adverse events)
Trial: 37028614
Drug: Breast cancer
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast cancer survivors without breast implants
Trial: 37028614
Drug: Women who
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who received breast augmentation surgery
Trial: 37029122
Drug: NITD609, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NITD609, an orally administered PfATPase inhibitor
Trial: 37029122
Drug: TD-6450, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD-6450, an orally-administered NS5A hepatitis C virus inhibitor
Trial: 37029298
Drug: 111 MBq
RxNorm normalized name: dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 111 MBq ± 10% dose
Trial: 37029431
Drug: High-dose tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tranexamic acid (20 mg/kg bolus + 5 mg/kg continuous infusion)
Trial: 37029431
Drug: Low-dose tranexamic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tranexamic acid (10 mg/kg bolus + 1 mg/kg continuous infusion)
Trial: 37029555
Drug: High-dose device-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose device-guided breathing intervention (n=14)
Trial: 37029555
Drug: Low-dose device-guided
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose device-guided breathing intervention (n=14)
Trial: 37030280
Drug: Maintenance olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance olaparib (400 mg twice daily)
Trial: 37030491
Drug: Digital Health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Health Nudging via daily smartphone messages for 12 weeks
Trial: 37030570
Drug: Empirical antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antibiotic treatment (cefepime, ceftriaxone, ceftazidime, imipenem, meropenem)
Trial: 37030570
Drug: Initial antibiotic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antibiotic treatment
Trial: 37031462
Drug: CD28/CD27-based CAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD28/CD27-based CAR T-cells therapy
Trial: 37031462
Drug: 4-1BB-based CAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-1BB-based CAR T-cells therapy
Trial: 37031691
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 supplementation (50 μg oral daily)
Trial: 37031827
Drug: Classical psychedelic
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical psychedelic drugs
Trial: 37031827
Drug: Non-classical psychedelic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-classical psychedelic drugs
Trial: 37032401
Drug: Two cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of neoadjuvant sintilimab plus chemotherapy
Trial: 37032401
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of neoadjuvant sintilimab plus chemotherapy
Trial: 37034122
Drug: Lobeglitazone, empagliflozin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone, empagliflozin, and metformin triple therapy
Trial: 37034122
Drug: Empagliflozin and
RxNorm normalized name: Empagliflozin and Linagliptin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin and metformin dual therapy
Trial: 37034344
Drug: LDL-C 1.8-<2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C 1.8-<2.6 mmol/L
Trial: 37034344
Drug: LDL-C ≥2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C ≥2.6 mmol/L
Trial: 37034685
Drug: Ivosidenib (AG-120),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivosidenib (AG-120), an FDA-approved mutant IDH1 inhibitor, used as a wtIDH1 inhibitor under nutrient-deprived conditions.
Trial: 37034685
Drug: Chemotherapy (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (specific agents not mentioned), which induces expression of wtIDH1.
Trial: 37035740
Drug: AAV9 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV9 gene therapy, early postnatal administration
Trial: 37036155
Drug: Fluconazole 150-mg
RxNorm normalized name: fluconazole 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 150-mg capsule (test)
Trial: 37036155
Drug: Fluconazole 150-mg
RxNorm normalized name: fluconazole 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 150-mg capsule (reference)
Trial: 37036404
Drug: 1-dose HAV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-dose HAV vaccine
Trial: 37036404
Drug: 2-dose HAV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose HAV vaccine administered 4 weeks apart
Trial: 37036404
Drug: 2-dose HAV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose HAV vaccine (subgroup analysis)
Trial: 37036416
Drug: Lutein (L)
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lutein (L) supplementation
Trial: 37036560
Drug: Facilitated subcutaneous
RxNorm normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated subcutaneous immunoglobulin (fSCIG) treatment
Trial: 37036671
Drug: AZD8186 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8186 (120 mg BID, 5 days on/2 days off) plus paclitaxel (80 mg/m2, days 1, 8, and 15) every 4 weeks
Trial: 37036722
Drug: Avalglucosidase alfa
RxNorm normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Avalglucosidase alfa (20 mg/kg by intravenous infusion every other week for 49 weeks)
Trial: 37036756
Drug: Riluzole 100
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole 100 mg PO BID + Sorafenib 400 mg AM/200 mg PM (MTD)
Trial: 37036783
Drug: Telehealth intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telehealth intervention for pediatric obesity; details on dosage and duration not available.
Trial: 37036843
Drug: Health-coach guided
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health-coach guided diet and exercise intervention (16 weekly sessions in family home)
Trial: 37037585
Drug: Large tumor-associated
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large tumor-associated macrophages (L-TAMs)
Trial: 37037585
Drug: Distribution of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distribution of L-TAMs
Trial: 37037780
Drug: delgocitinib cream
RxNorm normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: delgocitinib cream 20 mg/g
Trial: 37037780
Drug: cream vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream vehicle
Trial: 37037948
Drug: Pen-administered low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pen-administered low-dose dasiglucagon
Trial: 37038006
Drug: Weekly carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly carboplatin (area under the curve 1.5 mg/ml)
Trial: 37038005
Drug: Atezolizumab therapy
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab therapy
Trial: 37038105
Drug: Guided Self-rehabilitation
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided Self-rehabilitation Contract (GSC) involving daily self-rehabilitation program focusing on three facial muscle groups (Frontalis, Orbicularis oculi, Zygomatici) for six months.
Trial: 37038159
Drug: upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 15 mg (UPA15)
Trial: 37038159
Drug: adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab 40 mg (ADA)
Trial: 37039068
Drug: Common workflows
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common workflows for referring clients to treatment
Trial: 37039338
Drug: Extemporaneously compounded
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extemporaneously compounded enteral caffeine base solution
Trial: 37039792
Drug: Personalized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized treatment
Trial: 37039792
Drug: Lisinopril vs
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril vs Hydrochlorothiazide
Trial: 37039792
Drug: Lisinopril vs
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril vs Amlodipine
Trial: 37039792
Drug: Lisinopril vs
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril vs Candesartan
Trial: 37039791
Drug: TXA-127 (0.5-mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA-127 (0.5-mg/kg intravenous infusion once daily for 5 days)
Trial: 37039791
Drug: TRV-027 (12-mg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV-027 (12-mg/h continuous intravenous infusion for 5 days)
Trial: 37039790
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (n=231)
Trial: 37039948
Drug: faricimab 6
RxNorm normalized name: FARICIMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: faricimab 6 mg up to every 16 weeks (Q16W) after 4 initial Q4W doses
Trial: 37039948
Drug: aflibercept 2
RxNorm normalized name: ziv-aflibercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aflibercept 2 mg Q8W after 3 initial Q4W doses
Trial: 37039967
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (1 g twice daily, starting from 5 days preoperatively until 10 days postoperatively)
Trial: 37039967
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (1 g twice daily)
Trial: 37040046
Drug: MK-8353/selumetinib 100/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8353/selumetinib 100/50 mg
Trial: 37040046
Drug: MK-8353/selumetinib 150/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8353/selumetinib 150/75 mg
Trial: 37040046
Drug: MK-8353/selumetinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8353/selumetinib (all doses)
Trial: 37040046
Drug: MK-8353/selumetinib 50/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8353/selumetinib 50/25 mg and 100/50 mg
Trial: 37040086
Drug: Bivalent HPV
RxNorm normalized name: HPV, bivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent HPV 16/18 vaccine
Trial: 37040116
Drug: Lecanemab 10
RxNorm normalized name: LECANEMAB 100 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [LEQEMBI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecanemab 10 mg/kg monthly
Trial: 37041046
Drug: Ketamine mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine mouthwash (4 times daily for 2 weeks)
Trial: 37041057
Drug: Oral immunonutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunonutritional supplement (INS) for 6 months